Manager × security

Bellevue Group AG NBIX holdings history

Who else holds this security? →

NEUROCRINE BIOSCIENCES INC · CUSIP 64125C109 · CIK 1674546

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Bellevue Group AG reported 24.04K NBIX (shares), valued at $4.05M, or 0.09% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.09%
Shares
24.04K
24,037
Reported value
$4.05M
USD

Shares increased 417.37%; reported value increased 561.87%, and weight changed +0.08 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.09%24,037SEC filing ↗Filed Aug 14, 2026
Q1 20260.01%4,646SEC filing ↗Filed May 15, 2026
Q4 20254.58%1,703,304SEC filing ↗Filed Feb 17, 2026
Q3 20255.14%1,763,105SEC filing ↗Filed Nov 14, 2025
Q2 20255.04%1,820,000SEC filing ↗Filed Aug 14, 2025
Q1 20254.51%1,820,000SEC filing ↗Filed May 14, 2025
Q4 20244.78%1,820,000SEC filing ↗Filed Feb 14, 2025
Q3 20243.48%1,863,800SEC filing ↗Filed Nov 14, 2024
Q2 20244.25%1,898,640SEC filing ↗Filed Aug 14, 2024
Q1 20244.32%2,055,874SEC filing ↗Filed May 15, 2024
Q4 20234.90%2,430,500SEC filing ↗Filed Feb 14, 2024
Q3 20234.68%2,583,550SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20234.68%2,583,550$290.65MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 20234.90%2,430,500$320.24MShares decreased 5.92%; reported value increased 10.18%, and weight changed +0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20244.32%2,055,874$283.55MShares decreased 15.41%; reported value decreased 11.46%, and weight changed -0.58 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20244.25%1,898,640$261.39MShares decreased 7.65%; reported value decreased 7.82%, and weight changed -0.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20243.48%1,863,800$214.75MShares decreased 1.83%; reported value decreased 17.84%, and weight changed -0.77 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20244.78%1,820,000$248.43MShares decreased 2.35%; reported value increased 15.68%, and weight changed +1.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20254.51%1,820,000$201.29MShares unchanged; reported value decreased 18.97%, and weight changed -0.27 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2025
Q2 20255.04%1,820,000$228.76MShares unchanged; reported value increased 13.64%, and weight changed +0.53 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20255.14%1,763,105$247.50MShares decreased 3.13%; reported value increased 8.20%, and weight changed +0.10 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20254.58%1,703,304$241.58MShares decreased 3.39%; reported value decreased 2.39%, and weight changed -0.56 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20260.01%4,646$612.06KShares decreased 99.73%; reported value decreased 99.75%, and weight changed -4.57 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20260.09%24,037$4.05MShares increased 417.37%; reported value increased 561.87%, and weight changed +0.08 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Bellevue Group AG · NEUROCRINE BIOSCIENCES INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1674546","quarter":"2026Q2","cusip":"64125C109"}

get_institutional_manager_history
{"cik":"1674546","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.